Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SILO PharmaSILO 42 3-1 Month Momentum % is -40.94% as of Sep. 11, 2026. GuruFocus rates SILO with a GF Score™ of 42/100 and a GF Value™ of $3.44 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,384 Biotechnology companies, SILO Pharma ranks worse than 94.15% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-11), SILO Pharma's 3-1 Month Momentum % is -40.94%.
The industry rank for SILO Pharma's 3-1 Month Momentum % or its related term are showing as below:
SILO's 3-1 Month Momentum % is ranked worse than 94.15% of 1384
companies
in the Biotechnology industry
Industry Median: 2.12
vs SILO: -40.94
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
SILO Pharma 3-1 Month Momentum % Related Terms
SILO vs ELAB, GLMD, APVO: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, SILO Pharma's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SILO Pharma 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SILO Pharma's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where SILO Pharma's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SILO Pharma (SILO) has a 3-1 Month Momentum % of -40.94% as of Sep. 11, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on SILO Pharma and its competitors. According to the industry distribution chart, SILO Pharma ranks #1303 out of 1384 companies in the Biotechnology industry, placing it in the top 94.1%.
Is SILO Pharma's 3-1 Month Momentum % too high?
SILO Pharma's current 3-1 Month Momentum % is -40.94%. Based on the distribution chart, SILO Pharma ranks #1303 out of 1384 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SILO Pharma has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SILO Pharma's 3-1 Month Momentum % compare to ELAB and GLMD?
According to the Biotechnology industry distribution chart, SILO Pharma ranks #1303 out of 1384 companies for 3-1 Month Momentum %. This places SILO Pharma in the lower half of its industry. The industry median 3-1 Month Momentum % is 2.12. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
The median 3-1 Month Momentum % among Biotechnology companies is 2.12, based on 1,384 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on SILO Pharma and its competitors. For the Biotechnology industry, the median 3-1 Month Momentum % is 2.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SILO Pharma's current 3-1 Month Momentum % is -40.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SILO Pharma stock overvalued right now?
Based on GuruFocus' analysis, SILO Pharma (SILO) is currently considered Possible Value Trap. The stock's GF Value™ is $3.44, compared to a current price of $2.10 — trading 39% below its estimated fair value. The current 3-1 Month Momentum % is -40.94%. SILO Pharma's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For SILO Pharma (SILO), the current 3-1 Month Momentum % is -40.94% as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SILO Pharma (SILO) Overvalued in 2026?
Based on GuruFocus' analysis, SILO Pharma stock appears to be undervalued.
The current stock price of $2.10 is trading 39% below its estimated GF Value™ of $3.44.
GuruFocus considers SILO Pharma to be Possible Value Trap.
Key valuation signals for SILO:
3-1 Month Momentum %: -40.94%
GF Value™: $3.44 vs. price of $2.10 (39% below fair value)
No single metric tells the full story. See the SILO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.
42GF Score
Get the complete analysis for SILO
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SILO has been successfully added to your 
